Introducing the IMED Biotech Unit What science can do Introduction What science can do At AstraZeneca, our purpose is to push the Our IMED Biotech Unit applies its research and Our approach to R&D development capabilities and technologies to The IMED Biotech Unit plays a critical boundaries of science to deliver life-changing accelerate the progress of our pipeline. Through role in driving AstraZeneca’s success. Working together with MedImmune, medicines. We achieve this by placing science great collaboration across our three science units, our global biologics arm and Global we are confident that we can deliver the next wave Medicines Development (GMD), our at the centre of everything we do. late-stage development organisation, of innovative medicines to transform the lives of we are ensuring we deliver an innovative patients around the world. and sustainable pipeline. Pancreatic beta cells at different Eosinophil prior to Minute pieces of circulating tumour DNA stages of regeneration apoptosis (ctDNA) in the bloodstream IMED Biotech Unit MedImmune Global Medicines Development Focuses on driving scientific advances Focuses on biologics research and Focuses on late-stage development in small molecules, oligonucleotides and development in therapeutic proteins, of our innovative pipeline, transforming other emerging platforms to push the monoclonal antibodies and other next- exciting science into valued new boundaries of medical science. generation molecules to attack a range medicines and ensuring patients of diseases. around the world can access them. It’s science that compels us to push the boundaries of what is possible. We trust in the potential of ideas and pursue them, alone and with others, until we have transformed the treatment of disease. Nanoparticles circulating in the blood stream 02 What science can do Introducing the IMED Biotech Unit 03 Our IMED Biotech Unit This is an exciting time to be Oncology; Cardiovascular and part of the Innovative Medicines Metabolic Diseases (CVMD); and Early Development (IMED) and Respiratory, Inflammation Biotech Unit. Our IMED teams and Autoimmunity (RIA). By and their passion for science remaining committed to working We are committed to driving scientific advances mean that we are now seeing openly and collaboratively our breakthrough discoveries with the best people and the in small molecules, nucleotides and other translate into medicines which best partners we are confident emerging technology platforms to push the can improve the lives of patients that we can gain a new with serious diseases, for understanding of disease to boundaries of medical science. which current treatments are deliver life-changing medicines.” limited. We are fuelling a world- Mene Pangalos class AstraZeneca pipeline Executive Vice President IMED Biotech Unit and Global Business Development across our main therapy areas: Each year we invest in excess of of science into drug discovery and $1 billion in discovering and developing ultimately innovative medicines. the next generation of life-changing We are pioneering new approaches medicines, from initial target selection to Open Innovation, creating a more through to the end of Phase II trials. permeable research environment where We employ over 2,300 scientists and our scientists can freely share their undertake research on a truly global ideas and know-how, and collaborate scale, operating vibrant science centres on projects with the very best academic across three continents. scientists. We remain committed to a Partnering and collaboration is a way culture of openness and will continue of life for our teams. We work alongside to identify innovative ways to connect scientists at many of the world’s leading the great science happening in our academic institutions to increase our laboratories with the best external understanding of disease physiology science from around the world. and help accelerate the translation We believe in the potential of ground-breaking science to transform the lives of patients. We do this by focusing on three key priorities: Fostering a culture where science Creating an environment open for Challenging conventional thinking, thrives, one that is dynamic, agile and innovation, where our teams work side we encourage our people to apply entrepreneurial by side with our academic and industry scientific rigour by challenging the way partners to make the next breakthrough we do things CRISPR (clustered regularly interspaced palindromic repeats) gene editing tool 04 What science can do Introducing the IMED Biotech Unit 05 Where science thrives We are achieving scientific leadership through a dynamic, agile and entrepreneurial culture that feels like a biotech but has the resources of a major global pharmaceutical company. IMED Biotech Unit by numbers at end of 2016 Inspiring great scientists Delivering a step change Our commitment to scientific leadership in R&D productivity rests on our ability to attract and retain and output the best scientists. Nowhere is this commitment more evident than in the Since it was formed in 2010, the way we recruit, develop and inspire IMED Biotech Unit has helped deliver our people. We want to attract the sustainable improvements in R&D brightest minds, the best talent, the productivity across AstraZeneca. We >95% boldest innovators - people who share have improved our success rates from ~2,300 our passion for science and belief of IMED projects first time in human and successful people with a passion in the possible. In return, we offer a completion of Phase III from 3.5 per with Personalised working environment that truly reflects cent to over 15 per cent - a clear 40 for science our ambition to push the boundaries improvement over the current industry Healthcare approach high impact of science. A place where curiosity, average of four per cent. Even more innovation and collaboration flourish, importantly, this is translating into the publications in 2016 where drive and determination is delivery of new medicines, with drugs like rewarded and where great science olaparib, osimertinib and CAZ AVI having comes alive. graduated to a successful launch. We believe that great science comes Personalised Healthcare (PHC) is at the from diverse teams with different heart of our science based approach to backgrounds and the vision for our drug development. We have invested workforce is that it reflects the diversity heavily in the skills, partnerships and of our patient population. That’s why we technology to achieve this, with 95 per are committed to creating an inclusive cent of our small molecule pipeline and environment for our people. more than 80 per cent of our clinical ~1,000 pipeline now following a PHC approach. ongoing Building our scientific collaborations reputation We are entrepreneurs in science, pushing the boundaries of what’s $13.5M possible each and every day. That’s why we have cultivated an environment generated from Open of excellence together with a strong track-record of publications. Our $1 Innovation entrepreneurial spirit gives our scientists Over $1 billion invested the courage to take smart risks and 38% not be discouraged by failure. We in scientific research of women in senior empower our scientists to not only keep each year abreast of the latest developments and scientific roles breakthroughs, but to drive them. 06 What science can do Introducing the IMED Biotech Unit 07 We call this our Both our IMED Biotech Unit teams and 5R framework our Early Stage Portfolio Committee Focusing on quality (ESPC) use this framework to ensure we We have established a culture where are progressing the right projects, asking our teams are ‘truth seeking’ in their the right questions and making the right not quantity behaviour and rigorous in their approach decisions at key review points throughout to asking the critical ‘killer’ questions. the drug development process. Rather than being rewarded for hitting Lessons learned from the fate of AstraZeneca’s drug the next milestone, our scientists are pipeline: a five-dimensional framework Cook et al rewarded for thinking about what Nature Reviews Drug Discovery 13, 419–431 (2014) The 5R framework emphasises quality it would take to deliver a viable, differentiated medicine. rather than quantity in our R&D. That’s why a sixth critical factor is having the right culture. Oncology tumour drivers – cell surface and lipid bilayer with receptor Our 5R framework Right safety Differentiated and clear safety margins Right target Understanding Strong link between of secondary Right commercial target and disease pharmacology risk opportunity Understanding Differentiated Differentiated value efficacy of reactive metabolites, proposition versus Available and genotoxicity, drug- future standard of care predictive drug interactions Focus on market biomarker Understanding of access, payer and target liability provider Right tissue Personalised healthcare strategy, Adequate Right patients including diagnostics bioavailability and and biomarkers tissue exposure Identification of the most responsive Definition of PD patient population biomarkers Definition of risk- Clear understanding benefit for given of pre-clinical and population clinical PK/PD Understanding of drug-drug interactions 08 What science can do Introducing the IMED Biotech Unit 09 Neuroscience We also pursue opportunity driven Our therapeutic focus projects in Neuroscience. We have made a long-term commitment to neuroscience, with ongoing investment The future of treatment for many of today’s to